Low ALK FISH positive metastatic non-small cell lung cancer (NSCLC) patients have shorter progression-free survival after treatment with ALK inhibitors.

Toruner, Gokce A

Low ALK FISH positive metastatic non-small cell lung cancer (NSCLC) patients have shorter progression-free survival after treatment with ALK inhibitors. [electronic resource] - Cancer genetics 02 2020 - 57-60 p. digital

Publication Type: Comparative Study; Journal Article

2210-7762

10.1016/j.cancergen.2019.12.003 doi


Adult
Aged
Aged, 80 and over
Anaplastic Lymphoma Kinase--analysis
Carbazoles--pharmacology
Carcinoma, Non-Small-Cell Lung--drug therapy
Clinical Decision-Making--methods
Crizotinib--pharmacology
False Positive Reactions
Female
Follow-Up Studies
Gene Rearrangement
Humans
In Situ Hybridization, Fluorescence--statistics & numerical data
Lung Neoplasms--drug therapy
Male
Middle Aged
Piperidines--pharmacology
Progression-Free Survival
Proportional Hazards Models
Protein Kinase Inhibitors--pharmacology
Retrospective Studies